Search | Page 2 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Durable long-term responses in patients with myelodysplastic syndromes treated with lenalidomide.

    ... despite previous treatment with recombinant erythropoietin . One patient began lenalidomide therapy because of ...

    Research Article last updated 07/20/2018 - 5:14pm.

  2. Weekly standard doses of rh-EPO are highly effective for the treatment of anemic patients with low-intermediate 1 risk myelodysplastic syndromes

    ... For more than 20 years erythropoietin (rHEPO) has largely been used to treat anemia in ...

    Research Article last updated 07/20/2018 - 5:14pm.

  3. Azacitidine in lower-risk myelodysplastic syndromes.

    ... data for azacitidine combination therapy with erythropoietin , granulocyte colony-stimulating factor, and valproic ...

    Research Article last updated 07/20/2018 - 5:14pm.

  4. Lenalidomide for treatment of myelodysplastic syndromes: current status and future directions.

    ... . In non-del(5q) patients, lenalidomide enhances erythropoietin receptor signaling. Future directions include use of ...

    Research Article last updated 07/20/2018 - 5:14pm.

  5. Pro-inflammatory proteins S100A9 and TNFα suppress erythropoietin elaboration in myelodysplastic syndromes

    Journal Title:  Haematologica Primary Author:  Cluzeau T Author(s):  Cluzeau ...

    Research Article last updated 10/20/2017 - 9:16am.

  6. Combination Study of Deferasirox and Erythropoietin in Patients With Low- and Int-1-risk Myelodysplastic Syndrome.

    ... of treatment with deferasirox combined with erythropoietin vs. erythropoietin alone on erythropoiesis in patients with low- and ...

    Clinical Trial last updated 04/27/2016 - 12:52pm.

  7. Diagnosis

    ... iron from your body. EPO level EPO, or erythropoietin , is a protein made by your kidneys. It is created in ...

    Topic section last updated 07/20/2018 - 5:15pm.

  8. Increasing the effectiveness of hematopoiesis in myelodysplastic syndromes: erythropoiesis-stimulating agents and transforming growth factor-β superfamily inhibitors

    ... erythropoiesis-stimulating agents (ESAs) such as erythropoietin (EPO) and mimetics are applied as first-line therapy in a ...

    Research Article last updated 10/23/2017 - 11:08am.

  9. Lenalidomide: Myelodysplastic syndromes with del(5q) and beyond

    ... restores effective erythropoiesis via enhancement of erythropoietin (EPO) receptor-initiated transcriptional response arising ...

    Research Article last updated 10/23/2017 - 10:58am.

  10. Increasing the effectiveness of hematopoiesis in myelodysplastic syndromes: erythropoiesis-stimulating agents and transforming growth factor-β superfamily inhibitors

    ... erythropoiesis-stimulating agents (ESAs) such as erythropoietin (EPO) and mimetics are applied as first-line therapy in a ...

    Research Article last updated 10/02/2017 - 10:10am.